Patent ID: 6696056
Filing Date: 2004-02-24
Classification: A61K,A61P

Abstract:
A pharmaceutical formulation of erythropoietin selected from the group consisting of:(a) a calcium chloride-free formulation comprising about 2000 IU erythropoietin, about 4.38 mg sodium chloride, 1.16 mg sodium phosphate monobasic dihydrate, 2.23 mg sodium phosphate dibasic dihydrate, about 5.00 mg glycine, about 0.30 mg Polysorbate 80, and adjusted to 1.0 mL with water; (b) a calcium chloride-free formulation comprising about 4000 IU erythropoietin, about 4.38 mg sodium chloride, 1.16 mg sodium phosphate monobasic dihydrate, 2.23 mg sodium phosphate dibasic dihydrate, about 5.00 mg glycine, about 0.30 mg Polysorbate 80, and adjusted to 1.0 mL with water; (c) a calcium chloride-free formulation comprising about 10,000 IU erythropoietin, about 4.38 mg sodium chloride, 1.16 mg sodium phosphate monobasic dihydrate, 2.23 mg sodium phosphate dibasic dihydrate, about 5.00 mg glycine, about 0.30 mg Polysorbate 80, and adjusted to 1.0 mL with water; and (d) a calcium chloride-free formulation comprising about 40,000 IU erythrdpoietin, about 4.38 mg sodium chloride, 1.16 mg sodium phosphate monobasic dihydrate, 2.23 mg sodium phosphate dibasic dihydrate, about 5.00 mg glycine, about 0.30 mg Polysorbate 80, and adjusted to 1.0 mL with water.